Is dose-dependent response to bacillus Calmette-Guérin treatment in urothelial carcinoma?

Fabricio Racca, Rafael Morales-Barrera, Joan Carles

    Research output: Contribution to journalArticleResearchpeer-review

    Abstract

    © Translational Cancer Research. All rights reserved. Bacillus Calmette-Guérin (BCG) intravesical instillation therapy has been established as a standard of care treatment for high-risk non-muscle invasive urothelial carcinoma (NMIUC). To date, many clinical have demonstrated a direct antitumor activity, prevention of tumor recurrence, reductions in tumor progression and, consequently, tumor specific mortality and improvement in overall survival. Nevertheless, the local adverse events arising from BCG intravesical account for about one-third of treatment discontinuations. Strategies to minimize the side effects are needed.
    Original languageEnglish
    Pages (from-to)S179-S181
    JournalTranslational Cancer Research
    Volume6
    DOIs
    Publication statusPublished - 1 Jan 2017

    Keywords

    • Bacillus Calmette-Guérin (BCG)
    • High doses
    • Non-muscle invasive (NMI)
    • Standard doses (SD)
    • Toxicity
    • Urothelial carcinoma (UC)

    Fingerprint Dive into the research topics of 'Is dose-dependent response to bacillus Calmette-Guérin treatment in urothelial carcinoma?'. Together they form a unique fingerprint.

  • Cite this